26.10.2023 • News

EuroAPI Announces New Governance

EuroAPI's Board of Directors decided that Karl Rotthier would step down as CEO, effective October 30, 2023. They initiated the search for a new CEO and appointed Viviane Monges, the current Board Chair, as interim CEO until a permanent successor is found, while she continues her role as Board Chair.

The Board of Directors also appointed Elizabeth Bastoni, Chair of the Nominations and Compensation Committee, as the Independent Lead-Director to oversee the company's governance and engage with shareholders on Board-related matters.

The Board of Directors thanked Karl Rotthier for his contributions to EuroAPI since 2021, notably during EuroAPI’s early days, establishing the Company as a new independent major active pharmaceutical ingredient (API) and contract development and manufacturing organization (CDMO) actor on the market. The Board will continue to support the Group’s transformation in a fast-evolving environment and will actively oversee the execution of the strategic review announced earlier this month.

Viviane Monges, Chair of EuroAPI’s Board of Directors appointed Chief...
Viviane Monges, Chair of EuroAPI’s Board of Directors appointed Chief Executive Officer for an interim period, effective October 30, 2023. © EuroAPI
Karl Rotthier to step down as Chief Executive Officer, effective October 30,...
Karl Rotthier to step down as Chief Executive Officer, effective October 30, 2023. © EuroAPI

Company

Logo:

EuroAPI

15 rue Traversière
75012 Paris
France

Company contact







From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.